Skip to main content

Table 1 Summary of the number of piglets with clinical signs and S. suis isolation.

From: Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets

  Locomotion CNS/other severe clinical signs S. suis in blood Total S. suis isolation
Group 1, Alhydrogel®     
Vaccine 8/9a 6/10 6/8b 8/10
Placebo 10/10 6/10 5/8b 9/10
Group 2, Emulsigen®-D     
Vaccine 8/9c 7/9c 7/9c 7/9c
Placebo 9/9a 7/10 8/9b 9/10
Group 3, Quil-A®     
Vaccine 10/10 8/10 5/10 10/10
Placebo 10/10 6/10 5/10 8/10
Group 4, Montanide™ ISA 206     
Vaccine 7/10 6/10 4/10 6/10
Placebo 9/9a 9/10 7/9b 9/10
Group 5, Montanide™ ISA 61     
Vaccine 7/10 0/10 0/10 3/10
Placebo 10/10 7/10 7/10 9/10
Group 6, Montanide™ ISA 201     
Vaccine 8/9a 4/10 2/9b 9/10
Placebo 7/7a 7/10 2/7b 10/10
  1. a Piglets died at Day 1 thus locomotion signs could not be collected.
  2. b Blood could not be collected from one or more animals.
  3. c One piglet in the vaccine group died before the second vaccination due to causes not related to the S. suis infection.